The rabbit gingival tissue response to retraction liquids and tetrahydrozoline

Kostič, I.; Mihailović, D.; Najman, Stevo; Stojanović, Sanja; Kostić, Milena

doi:10.2298/vsp1401046k

Cited by 5 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vasoconstrictive gingival retraction agents should have a sufficient clinical efficiency without local and minimal systemic side effects (18)(19)(20). A systemic reaction is infrequent in some vasoconstrictor materials of the alpha agonists-including tetrahydrozoline, oxymetazoline, and phenylephrine-that are commonly used as eye and nose decongestant drops.…”

Section: Discussionmentioning

confidence: 99%

“…The effect of retraction agents on the generation of free radicals and promotion of oxidative stress was examined. Oxidative stress was evaluated by DCF assay after different times of incubation (5,20, and 25 min) with various retraction agents using 1:20 concentration. The increase in the level of free radicals was proportional to the time of incubation in HGFs.…”

Section: Level Of Rosmentioning

confidence: 99%

“…Previous studies on the comparative histological evaluation of the response of gingival tissue in beagle dogs and rabbits after exposure to the selected CRAs and ERAs revealed a low damaging potential of 0.05% HCl-tetrahydrozoline (18)(19)(20). Several in vitro studies on various cell lines have shown a significantly higher cytotoxicity of astringents than that of the vasoconstrictors (21)(22)(23)(24)(25)(26).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

In�vitro effects of vasoconstrictive retraction agents on primary human gingival fibroblasts

et al. 2020

View full text Add to dashboard Cite

The biological activity of chemical retraction/ displacement agents in surrounding periodontal tissues is of unquestionable importance, but the activity of these agents has not been completely elucidated. In the present study, we aimed to evaluate the in vitro effects of vasoconstrictive retraction agents on primary human gingival fibroblasts (HGFs). A total of six commercial adrenergic solutions (0.05 and 0.01% HCl-epinephrine, two based on 0.05% HCl-tetrahydrozoline, 0.05% HCl-oxymetazoline, and 10% HCl-phenylephrine) and three experimental gel formulations (EG-1, EG-2, and EG-3) were used to treat primary HGFs. The biological effect of the retraction treatment on the expression of collagen types I and III was detected by performing immunocytochemical analysis. The generation of reactive oxygen species triggered by the retraction agents were evaluated by using the dichlorofluorescein (DCF) fluorescent probe. The effect of retraction agents on the expression of fibronectin was visualized by confocal laser scanning microscopy. According to the results, experimental retraction gels did not limit the expression of collagen types I and III. EG-3 even induced the synthesis of both types of collagen. The DCF assay indicated oxidative stress similar to the control cells for most of the selected retraction agents. Experimental gels did not cause degradation of the cellular shape and morphology of the primary HGFs. The proposed experimental retraction gels in the present study demonstrated higher biocompatibility with primary HGFs, suggesting their use as clinical vasoconstrictive agents for the application of gingival retraction with minimal damage to periodontal tissues.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Level Of Rosmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

In�vitro effects of vasoconstrictive retraction agents on primary human gingival fibroblasts

et al. 2020

View full text Add to dashboard Cite

show abstract

“…It can also increase postoperative pain [ 13 , 14 ]. Tissue injury was observed after the application of epinephrine with retraction cord in high dose (80 mg/ml) in animals [ 15 – 17 ]. However, the cytotoxic effect of epinephrine (5 mg/ml) was not observed on human gingival fibroblast [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

Epinephrine penetrates through gingival sulcus unlike keratinized gingiva and evokes remote vasoconstriction in human

et al. 2020

View full text Add to dashboard Cite

Background It has been demonstrated in non-oral tissues that the locally evoked vasoconstriction could elicit remote vasoconstriction. This study aimed to investigate the spreading vasoconstrictor effects of epinephrine in the gingiva. Methods Gingival blood flow (GBF) was measured by laser speckle contrast imager in 21 healthy volunteers. In group A, two wells were fabricated from orthodontic elastic ligature and placed 2 mm apically to the free gingival margin at the mid buccal line of 12 (test side) and 21 (control side) teeth. The GBF was measured in the wells and tightly apical, coronal, distal and mesial to the wells. In group B, the wells were made on the buccal surface of the same teeth, including the gingival sulcus. Four regions were selected for measurement from the gingival margin reaching the mucogingival line (coronal, midway1, midway2 and apical). After the baseline recording, 3 µg epinephrine was applied into the test, and physiological saline into the control well. The GBF was recorded for 14 min. The gingival thickness was measured with a PIROP Ultrasonic Biometer. Results In group A, the GBF did not increase or decrease after the application of epinephrine. In group B, the GBF significantly decreased in all regions of the test side and remained low for the observation period. The vasoconstriction appeared with delays in more apical regions (at min 1 in the coronal and the midway1, at min 2 in the midway2, at min 4 in the apical region). Similarly, the amount of the decrease at 14 min was the largest close to sulcus (− 53 ± 2.9%), followed by the midway1 (− 51 ± 2.8%) and midway2 (− 42 ± 4.2%) and was the lowest in the apical region (− 32 ± 5.8%). No correlation was found between GBF and gingival thickness. Conclusion Epinephrine could evoke intense vasoconstriction propagating to the mucogingival junction, indicating the presence of spreading vasoconstriction in the human gingiva. The attached gingiva is impermeable to epinephrine, unlike the gingival sulcus. This trial was registered in ClinicalTrials.gov titled as Evidence of Spreading Vasoconstriction in Human Gingiva with the reference number of NCT04131283 on 16 October 2019. https://clinicaltrials.gov/show/NCT04131283

show abstract